Collaboration aims to identify biological signatures and patient subpopulations most likely to benefit from BioAegis’ recombinant human plasma gelsolin (rhu-pGSN), a novel immune modulator for inflammatory diseases. NORTH BRUNSWICK, N.J., April 21, 2026 (GLOBE...
Prenosis Announces $20M BARDA Contract and $20M Series A Financing Round, Advancing Mission to Deliver Integrated Diagnostics and Therapeutics
Latest fundraising efforts accelerate further innovation in biology-based diagnostics and therapeutics for critical care conditions CHICAGO, IL – January 29, 2026 – Prenosis, a biology-based technology company delivering integrated diagnostics and therapeutics,...
Prenosis Named Winner of the 24th Annual Chicago Innovation Awards
Company’s AI-powered diagnostic is shaping the future of sepsis care CHICAGO, IL – November 14, 2025 – Prenosis has been named a winner of the 24th Annual Chicago Innovation Awards, the region’s foremost recognition of the most innovative new products and services...
Prenosis Named Finalist in 2025 Digital Health Hub Foundation Awards
Finalist recognition validates Prenosis’ pioneering work in AI-driven diagnostics for sepsis and its impact on critical care decision-making Chicago, IL – October 8, 2025 — Prenosis has been named a Finalist in the 2025 Digital Health Hub Foundation: Digital Health...
New ICD-10-PCS Code Available for AI Sepsis Diagnostic Tools
Prenosis’ Sepsis ImmunoScore™, Innovative Sepsis Diagnostic Technology, Now Supported by Enhanced Documentation and Reimbursement Pathway CHICAGO, IL – October 1, 2025 – The Centers for Medicare & Medicaid Services (CMS) has officially released the FY 2026...
Prenosis Named One of the Top 100 Finalists for the 24th Annual Chicago Innovation Awards
Chicago-based Prenosis recognized for pushing the boundaries of biology and AI in acute care innovation CHICAGO, IL – September 24, 2025 – Prenosis has been named one of the Top 100 Finalists for the 24th Annual Chicago Innovation Awards, which celebrates the most...
Prenosis Named Quarterfinalist in 2025 Digital Health Hub Foundation Awards
Recognition highlights Prenosis’ leadership in integrated diagnostics and therapeutics and its mission to bring clarity to critical care decisions CHICAGO, IL – September 15, 2025 – Prenosis has been selected as a quarterfinalist for the 2025 Digital Health Hub...
Sepsis ImmunoScore Named Honoree in Fast Company’s 2025 World Changing Ideas Awards
Annual Awards Recognize Innovative Companies and Projects Addressing the World’s Most Urgent Challenges CHICAGO, IL [June 10, 2025] — Prenosis is proud to announce that Sepsis ImmunoScore™ has been named an honoree of Fast Company ’s 202 5 World Changing Ideas...
Bobby Reddy, Jr. Named to TIME’s 2025 TIME100 Health List
Prenosis CEO and co-founder honored as one of the 100 most influential people in global health this year CHICAGO, IL – May 8, 2025 – Prenosis, Inc., a leader in precision diagnostics powered by artificial intelligence, today announced that its CEO and co-founder,...
Study published in the New England Journal of Medicine AI Concludes that the Sepsis ImmunoScore™, the First FDA-Authorized AI Tool for Sepsis, has both significant Diagnostic and Predictive Power
Groundbreaking NEJM AI Study Highlights the Ability of Prenosis’ Sepsis ImmunoScore™ to Holistically Predict Adverse Outcomes, Ushering in a New Era of Predictive Sepsis Tools Powered by AI CHICAGO , Dec. 4, 2024 /PRNewswire/ — A new study published in the...